Vardenafil dihydrochloride
Vardenafil dihydrochloride structure
|
Common Name | Vardenafil dihydrochloride | ||
|---|---|---|---|---|
| CAS Number | 224789-15-5 | Molecular Weight | 561.525 | |
| Density | N/A | Boiling Point | 692.2ºC at 760mmHg | |
| Molecular Formula | C23H34Cl2N6O4S | Melting Point | 214-216°C | |
| MSDS | N/A | Flash Point | 372.5ºC | |
| Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger | |
|
Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil.
Respir. Physiol. Neurobiol. 186(1) , 61-4, (2013) Vardenafil, a phosphodiesterase-5 inhibitor, is approved for the therapy of erectile dysfunction. However, in contrast to Sildenafil and Tadalafil, little is known about its effects on pulmonary hypertension. Four weeks after monocrotaline-administration rats... |
|
|
SOP conservative (medical and mechanical) treatment of erectile dysfunction.
J. Sex. Med. 10(1) , 130-71, (2013) Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male self-esteem and nearly all life domains including interpersonal, family, and business relationships.The... |
|
|
High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension.
Eur. J. Clin. Pharmacol. 69(2) , 197-207, (2013) To evaluate the pharmacokinetic parameters of a single oral dose of vardenafil in patients with pulmonary hypertension (PH).Sixteen patients with PH received vardenafil in single oral doses (20, 10 or 5 mg), and repeated blood sampling for up to 9 h was perfo... |
|
|
Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.
J. Biol. Chem. 287(49) , 41406-16, (2012) The 11 families of the Class I cyclic nucleotide phosphodiesterases (PDEs) are critical for regulation of cyclic nucleotide signaling. PDE5 (important in regulating vascular smooth muscle contraction) and PDE6 (responsible for regulating visual transduction i... |
|
|
Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation.
Endocrinology 153(11) , 5546-55, (2012) Phosphodiesterase type 5 (PDE5) inhibitors have been demonstrated to improve lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). Because BPH is primarily driven by fibroblast-to-myofibroblast trans-differentiation, this study aimed t... |
|
|
Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
Ann. Pharmacother. 47(2) , 278-83, (2013) To determine the efficacy of phosphodiesterase inhibitors for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).MEDLINE and PubMed were searched from January 1, 2000, to October 31, 2012, using the MeSH terms pho... |
|
|
The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers.
J. Sex. Med. 10(2) , 532-40, (2013) Utility of phosphodiesterase inhibitors (PDEi's) for the treatment of erectile dysfunction (ED) has been the focus of experimental and clinical studies. However, public preferences, attitudes, and experiences with PDEi's are rarely addressed from a population... |
|
|
Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil.
J. Pharm. Pharmacol. 64(8) , 1074-83, (2012) We aimed to characterize the efflux transport properties of vardenafil and sildenafil, and to compare the kinetics of these compounds via efflux transporters such as P-gp, BCRP and MRP2.We measured the basal-to-apical and apical-to-basal transport of vardenaf... |
|
|
Vardenafil ameliorates calcium mobilization in pulmonary artery smooth muscle cells from hypoxic pulmonary hypertensive mice.
Arch. Med. Res. 43(4) , 265-73, (2012) Vardenafil has been found to be potent in pulmonary hypertension; however, the underlying mechanisms remain poorly understood. To address this issue, we investigated the underlying mechanisms of vardenafil in the contribution of Ca(2+) signaling and mobilizat... |
|
|
Response to on-demand vardenafil was improved by its daily usage in hypertensive men.
Urology 80(4) , 858-64, (2012) To evaluate whether the response to on-demand vardenafil could be improved by its daily usage in hypertensive men with erectile dysfunction (ED) who previously did not answer to on-demand regime.Our main efficacy criterion was per patient percentage of positi... |